Penn's leading scientists in CAR-T and mRNA, Carl June and Drew Weissman, are among the company's founders.

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of ...

This is the second trial failure for AbbVie and Roche with Venclexta, which also came up short in the Canova study in patients with relapsed or refractory multiple myeloma who tested positive for ...

12.1% of patients on atogepant discontinued due to side effects vs. 29.6% on topiramate. 64.1% of atogepant users saw migraine days cut by half, compared to 39.3% for topiramate. Market-moving ...

By Denny Jacob AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average number of days per month when they experience migraine headaches.

AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average number of days per month when they experience migraine headaches.

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. The complaint filed in a Seattle court alleges that Genmab ...

We expect AbbVie to start recording the drug’s sales from the third quarter of 2025 and our model estimates that the drug could generate $28 million in sales this year. Emrelis also diversifies ...